We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+15.96%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$835M
AUM Growth
-$85.8M
(-9.3%)
Cap. Flow
+$31.1M
Cap. Flow
% of AUM
3.73%
Top 10 Holdings %
Top 10 Hldgs %
98.18%
Holding
15
New
2
Increased
2
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pharvaris
PHVS
|
+$103M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$47.9M |
| 3 |
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
|
+$4.67M |
| 4 |
Kura Oncology
KURA
|
+$1.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nurix Therapeutics
NRIX
|
+$42M |
| 2 |
GBIO
Generation Bio
GBIO
|
+$24.3M |
| 3 |
Olema Pharmaceuticals
OLMA
|
+$18.2M |
| 4 |
ALX Oncology
ALXO
|
+$14.8M |
| 5 |
Vaxcyte
PCVX
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $301M | 36.1% |
9,671,643
| – | – |
|
|
2
Pharvaris
PHVS
$2.28B
| $91.3M | 10.93% |
+3,261,926
| New | +$103M |
|
|
3
Aclaris Therapeutics
ACRS
$726M
| $85.7M | 10.26% |
3,399,034
+2,447,650
| +257% | +$47.9M |
|
4
Keros Therapeutics
KROS
$199M
| $85.1M | 10.19% |
1,382,641
-30,064
| -2% | -$1.9M |
|
5
Relay Therapeutics
RLAY
$4.1B
| $74M | 8.86% |
2,139,380
| – | – |
|
|
6
ALX Oncology
ALXO
$261M
| $58M | 6.94% |
785,945
-187,569
| -19% | -$14.8M |
|
|
7
Kura Oncology
KURA
$800M
| $52.3M | 6.26% |
1,849,947
+41,965
| +2% | +$1.33M |
|
|
8
Nurix Therapeutics
NRIX
$2.41B
| $38.5M | 4.61% |
1,238,456
-1,109,348
| -47% | -$42M |
|
9
Cytokinetics
CYTK
$10.5B
| $20.5M | 2.46% |
881,901
-554,091
| -39% | -$11.8M |
|
|
10
Olema Pharmaceuticals
OLMA
$1B
| $13M | 1.56% |
393,030
-425,000
| -52% | -$18.2M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $8.11M | 0.97% |
1,787,094
| – | – |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $3.68M | 0.44% |
350,000
| – | – |
|
|
DBTX
13
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $3.38M | 0.41% |
+297,711
| New | +$4.67M |
|
|
GBIO
14
DELISTED
Generation Bio
GBIO
| – | – |
-85,794
| Closed | -$24.3M |
|
|
15
Vaxcyte
PCVX
$7.81B
| – | – |
-465,821
| Closed | -$12.4M |
|
Similar funds
BCM
AG
FL
PVM
MFA
TCM
WW
CB
Foresite Capital Management IV's Q1 2021 Portfolio in Review
As of Q1 2021, Foresite Capital Management IV held 15 positions worth $835M, down 9.3% from $921M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Foresite Capital Management IV deployed $31.1M of net new capital in Q1 2021, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Pharvaris: 3,261,926 shares worth $91.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Nurix Therapeutics, an estimated $42M trimmed.
- Foresite Capital Management IV's largest Q1 2021 buy was Pharvaris: 3,261,926 shares worth $91.3M.
- Foresite Capital Management IV added most to Aclaris Therapeutics in Q1 2021, an estimated $47.9M increase.
- Foresite Capital Management IV's biggest Q1 2021 reduction was Nurix Therapeutics, cutting an estimated $42M.
- Foresite Capital Management IV fully exited Generation Bio in Q1 2021, selling an estimated $24.3M.
- Foresite Capital Management IV's ten largest holdings make up 98% of its $835M portfolio in Q1 2021.
- Foresite Capital Management IV opened 2 new positions and closed 2 in Q1 2021.
- Foresite Capital Management IV's portfolio value fell 9.3% quarter-over-quarter to $835M.
Based on Foresite Capital Management IV's 13F filing for Q1 2021, filed 17 May 2021.